

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

MAY 14 1999

ATTY DOCKET NO.
RPP:135D US

SERIAL NO.
08/644,289

APPLICANT(S) Molly F. Kulesz-Martin

FILING DATE
May 10, 1996

GROUP
1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

K	K	Kulesz-Martin, et al., "Endogenous p53 Protein Generated from Wild-Type Alternatively Spliced p53 RNA in Mouse Epidermal Cells", Mol. Cell. Bio., pp 1698-1708, 1994
W	W	Wu, et al., "Activities and Response to DNA Damage of Latent and Active Sequence-Specific DNA Binding Forms of Mouse p53", Proc. Natl. Acad. Sci, Vol. 94, pp. 8982-8987, 1997

EXAMINER

Yvonne Gier

DATE CONSIDERED

4/30/99

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-A820

(also form PTO-1449)

Patent and Trademark Office • U.S. DEPARTMENT OF COMMERCE

PAGE 1 OF 1

M. T. DAVIS

08/29/06

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY DOCKET NO.
RPP:135D US

SERIAL NO.: 08/644,289

APPLICANT(S): Molly F. Kulesz-Martin

FILING DATE: 5/10/96

GROUP: 1642



U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
yls- 4E	0 652 232 A1	5/10/95	EUROPE				✓

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

Wonne Efer

DATE CONSIDERED

7/30/99

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-A820

(also form PTO-1449)

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

PAGE 1 OF 1

M. T. DAVIS

08/29/06

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
RPP:135D US

SERIAL NO.
08/644,289

APPLICANT(S) Molly F. Kulesz-Martin

FILING DATE: 5-10-96

GROUP: ~~Unknown~~
1806

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
YE	92/13970	8/92	WO	—	—		
YE	EP-A-O-529 160	3/93	EP	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

YE		Arai, N., et al., (1986) Immunologically Distinct p53 Molecules Generated by Alternative Splicing. Mol. and Cell. Biol. 6, 3232-3239.
YE		Balmain, A., et al. (1982) Cloning and Characterization of the Abundant Cytoplasmic 7S RNA from Mouse Cells. Nucleic Acids Res. 10, 4259-4277.
YE		Bargonetti, J., et al. (1992) Site-Specific Binding of Wild-Type p53 to Cellular DNA is Inhibited by SV40 T Antigen and Mutant p53. Genes & Dev. 6, 1886-1898.
YE		Bayle, J. et al., (1995) The Carboxyl-Terminal Domain of the p53 Protein Regulates Sequence-Specific DNA Binding Through its Nonspecific Nucleic Acid Binding Activity, Proc. Nat. Acad. Sciences of USA, Vol. 92, No. 12, pg. 5729-5733.
YE		Burns, P.A., et al. (1991) Loss of Heterozygosity and Mutational Alterations of the p53 Gene in Skin Tumours of Interspecific Hybrid Mice. Oncogene 6, 2363-2369.
YE		Crook, T., et al. (1991) Modulation of Immortalizing Properties of Human Papillomavirus Type 16E7 by p53 Expression. J. Virol. 6, 505-510.
YE		Davies, R., et al. (1993) Antioxidants can Delay Liver Cell Maturation Which in Turn Affects γ -glutamyltranspeptidase Expression. Carcinogen. 14,47-52.

EXAMINER

Yvonne E. Lee

DATE CONSIDERED

3/26/97

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-A820

(also form PTO-1449)

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

PAGE 1 OF 4

M.T. DAVIS

08/29/06

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		MAIL ROOM AUG 26 1996	ATTY DOCKET NO. RPP:135D US	SERIAL NO. 08/644,289
		APPLICANT(S) Molly F. Kulesz-Martin		FILING DATE 5-10-96
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
✓			Eliyahu, D., et al. (1988) Meth A Fibrosarcoma Cells Express Two Transforming Mutant p53 Species. <i>Oncogene</i> 3, 313-321.	
✓			Farmer, G., et al. (1992) Wild-Type p53 Activates Transcription in vitro. <i>Nature</i> 358, 83-86.	
✓			Finlay, C.A., et al. (1989) The p53 Proto-Oncogene can Act as a Suppressor of Transformation. <i>Cell</i> 57, 1083-1093.	
✓			Fontoura, B.M.A. et al. (1992) p53 is Covalently Linked to 5.8S rRNA. <i>Mol. Cell. Biol.</i> 12, 5145-5151.	
✓			Foord, O.S., et al. (1991) A DNA Binding Domain is Contained in the C-Terminus of Wild Type p53 Protein. <i>Nucleic Acids Res.</i> 19, 5191-5198.	
✓			Foulkes, N.S., et al. (1992) More is Better: Activators and Repressors from the Same Gene. <i>Cell</i> 68, 411-414.	
✓			Gannon, J.V. et al. (1990) "Activating Mutations in p53 Produce a Common Conformational Effect. A Monoclonal Antibody Specific for the Mutant Form," <i>EMBO</i> 9:1595-1602.	
✓			Hainaut, P., et al. (1992) Interaction of Heat-Shock Protein 70 with p53 Translated in vitro evidence for Interaction with Dimeric p53 and for a Role in the Regulation of p53 Conformation. <i>EMBO J.</i> 11, 3513-3520.	
✓			Han, K., et al. (1990) Altered Levels of Endogenous Retrovirus-like Sequence (VL30) RNA During Mouse Epidermal Cell Carcinogenesis. <i>Mol. Carcinogenesis</i> 3:75-82.	
✓			Han, K., et al. (1992) Altered Expression of Wild-type p53 Tumor Suppressor Gene During Murine Epithelial Cell Transformation. <i>Cancer Research</i> 52, 749-753.	
✓			Han, K., et al. (1992) Alternatively Spliced p53 RNA in Transformed and Normal Cells of Different Tissue Types. <i>Nucleic Acids Res.</i> , 20(8), 1979-1981	
✓			Hupp, T.R., et al. (1992) Regulation of the Specific DNA Binding Function of p53. <i>Cell</i> 71, 875-886.	
✓			Jenkins, J.R., et al. (1984) Cellular Immortalization by a cDNA Clone Encoding the Transformation-Associated Phosphoprotein p53. <i>Nucleic Acids Res.</i> 12, 5609-5626.	
✓			Kastan, M.B., et al. (1991) Participation of p53 Protein in the Cellular Response to DNA Damage. <i>Cancer Research</i> 51, 6304-6311.	
✓			Kastan, M.B. et al. (1992) A Mammalian Cell Cycle Checkpoint Pathway Utilizing p53 and GADD45 is Defective in Ataxia-Telangiectasia. <i>Cell</i> 71, 587-597.	
✓			Kulesz-Martin, M. et al. (1985) Mouse Cell Clones for Improved Quantitation of Carcinogen-Induced Altered Differentiation. <i>Carcinogenesis</i> 6, 1245-1254.	
EXAMINER <i>Yvonne Eidel</i>			DATE CONSIDERED 3/26/97	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Form PTO-A820

(also form PTO-1449)

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

PAGE 2 OF 4

M. T. DAVIS 08/29/06

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		MAIL ROOM 1996	ATTY DOCKET NO. RPP:135D US	SERIAL NO. 08/644,289
		APPLICANT(S) Molly F. Kulesz-Martin		
		FILING DATE 5-10-96	GROUP Unknown 1806	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
✓		Kulesz-Martin, M. et al. (1986) Retinoic Acid Enhancement of an Early Step in the Transformation of Mouse Epidermal Cells <u>in vitro</u> . Carcinogenesis 7, 1425-1429		
✓		Kulesz-Martin, M. et al. (1989) Pemphigoid, Pemphigus and Desmoplakin as Antigenic Markers of Differentiation in Normal and Tumorigenic Mouse Keratinocyte Lines. Cell Tissue Kinet. 22, 279-290.		
✓		Kulesz-Martin, M. et al. (1991) Tumor Progression of Murine Epidermal Cells After Treatment <u>in vitro</u> with 12-O-Tetradecanoylphorbol-13-Acetate or Retinoic Acid. Cancer Research 51, 4701-4706.		
✓		Kulesz-Martin, M. et al. (1983) Properties of Carcinogen Altered Mouse Epidermal Cells Resistant to Calcium-Induced Terminal Differentiation. Carcinogen 4, 1367-1377.		
✓		Kulesz-Martin, M. et al., (1994) Endogenous Mouse p53 Protein Generated by Alternative Splicing, J. Cellular Biochemistry Supplement, Vol. 0, No. 18c, page 170.		
✓		Lane, D.P. (1992) p53, Guardian of the Genome. Nature 358, 15-16.		
✓		Milne, D.M., et al. (1992) Mutation of the Casein Kinase II Phosphorylation Site Abolishes the Anti-Proliferative Activity of p53. Nucleic Acids Res. 20, 5565-5570.		
✓		Milner, J. (1991) The Role of p53 in the Normal Control of Cell Proliferation. Current Opinion in Cell Biology 3, 282-286.		
✓		Milner, J. (1984) Different Forms of p53 Detected by Monoclonal Antibodies in Non-Dividing and Dividing Lymphocytes. Nature 20, 143-145.		
✓		Milner, J. et al. (1991) Cotranslation of Activated Mutant p53 with Wild Type Drives the Wild-Type p53 Protein into the Mutant Conformation. Cell 65, 765-774.		
✓		Momand, J., et al. (1992) The mdm-2 Oncogene Product forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation. Cell 69, 1237-1245.		
✓		Nigro, J.M., et al. (1992) Human p53 and CDC2Hs Genes Combine to Inhibit the Proliferation of Saccharomyces Cerevisiae. Mol. and Cell Biol. 12, 1357-1365.		
✓		Oren, M. et al. (1983) Molecular Cloning of a cDNA Specific for the Murine p53 Cellular Tumor Antigen. Proc. Natl. Acad. Sci. USA, 80, 56-59.		
✓		Prives, C., et al. (1993) The p53 Tumor Suppressor Protein: Meeting Review. Genes & Dev. 7:529-534.		
✓		Ro, Y.S., et al. (1993) p53 Protein Expression in Benign and Malignant Skin Tumours. Br. J. Dermatol. 12, 237-241.		
✓		Ruggeri, B., et al. (1991) Alterations of the p53 Tumor Suppressor Gene During Mouse Skin Tumor Progression. Cancer Research 51, 6615-6621.		
EXAMINER <i>Y. Anne Eder</i>		DATE CONSIDERED 3/26/97		
*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				


Form PTO-A820
(also form PTO-1449)

Patent and Trademark Office • U.S. DEPARTMENT OF COMMERCE

PAGE 3 OF 4

M. T. DAVIS

08/29/06

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY DOCKET NO. RPP:135D US	SERIAL NO. 08/644,289
		APPLICANT(S) Molly F. Kulesz-Martin			
		FILING DATE 5-10-96	GROUP Unknown 1806		
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)					
✓			Schneider, B.L., et al. (1993) 7,12-Dimethylbenz[α]anthracene-Induced Mouse Keratinocyte Transformation Without Harvey ras Protooncogene Mutations. J. Invest. Dermatology, 101:595-599, 1993.		
✓			Seto, E., et al. (1992) Wild-Type p53 Binds to the TATA-Binding Protein and Represses Transcription. Proc. Natl. Acad. Sci. 89, 12028-12032.		
✓			Soussi, T., et al. (1990) Structural Aspects of the p53 Protein in Relation to Gene Evolution. Oncogene 5, 945-952.		
✓			Stenger, J.E., et al. (1992) Formation of Stable p53 Homotetramers and Multiples of Tetramers. Mol. Carcinogen. 5, 102-106.		
✓			Stephen, C.W., et al. (1992) Mutant Conformation of p53. Precise Epitope Mapping Using a Filamentous Phage Epitope Library. J. Mol. Biol. 225,577-583.		
✓			Sturzbecher, H.S., et al. (1992) A C-Terminal α-Helix Plus Basic Region Motif is the Major Structural Determinant of p53 Tetramerization. Oncogene 7, 1513-1523		
✓			Vogelstein, B. (1990) A Deadly Inheritance. Nature 348, 681-682.		
✓			Vogelstein, B., et al. (1992) p53 Function and Dysfunction. Cell 70, 523-526.		
✓			Wade-Evans, A., et al. (1985) Precise Epitope Mapping of the Murine Transformation-Associated Protein, p53. EMBO J. 4,699-706.		
✓			Weintraub, H., et al. (1991) The MCK Enhancer Contains a p53 Responsive Element. Proc. Natl. Acad. Sci. 88, 4570-4571.		
✓			Wolf, D., et al. (1985) Isolation of a Full-Length Mouse cDNA Clone Coding for an Immunologically Distinct p53 Molecule. Mol. and Cell Biol. 51, 127-132		
✓			Wolf, D., et al. (1984) Reconstitution of p53 Expression in a Nonproducer Ab-MuLV-Transformed Cell Line by Transfection of a Functional p53 Gene. Cell 38, 119-126.		
✓			Wu, Y. et al., (1994) Physiological Protein Variant of the Mouse p53 Tumor Suppressor Gene, Proc. of the American Assoc. for Cancer Research, Annual Mtg., Vol. 35, pg 605.		
✓			Wu, Y. et al., (1994) Wild-Type Alternatively Spliced p53: Binding to DNA and Interaction with the Major p53 Protein in vitro and in Cells, The EMBO Journal, Vol. 13, No. 20, pg. 4823-4830.		
✓			Yonish-Rouach, E., et al. (1993) p53-Mediated Cell Death: Relationship to Cell Cycle Control. Mol. and Cell. Biol. 13, 1415-1423.		
✓			Yonish-Rouach, E., et al. (1991) Wild-Type p53 Induces Apoptosis of Myeloid Leukaemic Cells that is Inhibited by Interleukin-6. Nature 352, 345-347.		
✓			Zambetti, G.P., et al. (1992) Wild-Type p53 Mediates Positive Regulation of Gene Expression Through a Specific DNA Sequence Element. Genes & Dev. 6, 1143-1159		
EXAMINER <i>Gordon Eder</i>			DATE CONSIDERED 3/26/97		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

M. T. DAVIS

08/29/06